Concepedia

James Izanec

JI

Statistics

Publications

9

Citations

514

H-Index

9

Active since

2004

Affiliations

Janssen (United States)(Current)

Janssen Scientific Affairs (United States)

Icahn School of Medicine at Mount Sinai

Northwestern University

University of California San Diego

James Izanec is an author at Janssen (United States) specializing in medicine, inflammatory bowel disease, and inflammatory bowel disease therapy.

Publications per year

2004–2023

9

Publications

9

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

Bruce E. Sands, Peter M. Irving, Timothy Hoops et al. · The Lancet · 2022 · 297 citations · Full text

Medicine, Clinical Sciences, Immunology +17

The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium

Amanda M. Johnson, Maria Barsky, Waseem Ahmed et al. · The American Journal of Gastroenterology · 2022 · 68 citations

Medicine, Clinical Sciences, Pharmacotherapy +15

OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE study

Peter M. Irving, B E Sands, Timothy Hoops et al. · Journal of Crohn s and Colitis · 2021 · 31 citations · Full text

Medicine, Clinical Sciences, Immunology +15

Achalasia Presenting After Operative and Nonoperative Trauma

Rupa N. Shah, James Izanec, David Friedel et al. · Digestive Diseases and Sciences · 2004 · 30 citations

Medicine, Neurological Surgery, Surgery +6

775d Ustekinumab Versus Adalimumab for Induction and Maintenance Therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE Study

Bruce E. Sands, Peter M. Irving, Timothy Hoops et al. · Gastroenterology · 2021 · 30 citations

Veterinary Medicine, Clinical Sciences, Immunology +15

1–5 of 9